Methods: Healthy adults (n= 90) of either gender were administered single dose of 300 mg
clopidogrel. Baseline, 4 h postdose, and day 7 assessment of platelet aggregation and …

Aims/objective Influence of genetic variations on the response of clopidogrel, an antiplatelet
drug is implicated. In the present study, the prevalence of single nucleotide polymorphisms …

Clopidogrel, an antiplatelet drug, is frequently prescribed to patients diagnosed with
ischemic diseases such as those suffering from acute coronary syndromes or ischemic …

Clopidogrel is an inhibitor of platelet ADP P2Y12 receptors and currently used for prevention
of stent thrombosis. Despite certain clinical benefit using this drug in patients undergoing …

Background It is essential to investigate the prevalence of CYP2C19 alleles that affect drug
metabolism. This study measures the allelic and genotypic frequencies of CYP2C19 loss-of …

The extent to which cytochrome P450 (CYP) 2C19 genotype influences the effectiveness of
clopidogrel remains uncertain due to considerable heterogeneity between studies. We used …

Clopidogrel is an antiplatelet drug used to prevent recurrent ischemic events after acute
coronary syndrome and/or coronary stent implantation. Single nucleotide polymorphisms …

Backgrounds and objectives Clopidogrel, an inhibitor of platelet ADP P2Y12 receptors,
plays an important role in the prevention of stent thrombosis. However, some patients do not …

Background Recent studies have reported the clinical importance of CYP2C19 and ABCB1
polymorphisms in an individualized approach to clopidogrel treatment. The aims of this …

Objective: To investigate the association between CYP2C19 and ABCB1 polymorphisms
and clopidogrel resistance (CR) in patients with cardiovascular disease in Beijing district …